Beacon Transcript – Spectrum Pharmaceuticals presented encouraging preliminary results for its lung cancer preclinical studies during the annual IASLC conference.
Spectrum Pharmaceuticals is a Henderson, Nevada-based biotechnology company. Although it offers fully integrated drug development and commercial operations, it is also more focused in two areas.
These two primary interest zones are Oncology and Hematology. The company announced new preclinical studies during an oral presentation.
The said presentation occurred as part of the IASLC World Conference on Lung Cancer. IASLC or the International Association for the Study of Lung Cancer held the conference in Vienna.
As the 17th such meeting, the World Conference took place in between December 4 to 7 in Vienna, Austria.
Rajesh C. Shrotriya, and M.D. and Chairman and Spectrum Pharmaceuticals CEO offered details. According to Rajesh, the company was honored by the chance to hold the oral presentation.
Their presentation’s subject were early preclinical poziotinib study results. The study is carried out by MD Anderson Cancer Center scientists.
According to early study, preliminary results, poziotinib may come to be used in certain NSCLC cases. Targeted NSCLC or non-small cell lung cancer patients have not responded to other inhibitors.
Their tumors are believed to have exon-20 mutations. EGFR inhibitors have been noticed to fail in generating a response to such mutations.
EGFR inhibitors or epidermal growth factor receptor inhibitors are a new anticancer therapeutics class. After being established as an oncogene, EGFR has started being the target of many such medicines.
Poziontinib is believed to cause a reaction due to its smaller size. As such, it may help inhibit EGFR cell growth with exon 20 insertions.
The preclinical study results, although early, may come as a new hope. If future studies and trials show its efficiency, it could help poor diagnosis patients.
Poor diagnosis lung cancer patients are the sufferers to have been given little or no other options. Current median progression-free survival time is estimated at around 1.5 months.
Spectrum is currently collaborating with a team of MD Anderson Cancer Center researchers. Their joint target is of expediting the present research.
Through it, they are trying to evaluate and serve the medical needs of this NSCLC part. According to Spectrum, this area’s medical need have yet to have been properly fulfilled.
According to study extracts, their poziotinib-based therapy should help inhibit the growth of the aforementioned EGFR cells.
Poziotinib was presented as a novel, oral-administration inhibitor. It should help block irreversibly the signaling through the EGFR, HER family. In other words, it should inhibit the tyrosine-kinase receptors of the Epidermal Growth Factor Receptor Family.
The HER inhibitor should also help prevent the mutations of such receptors. As such, poziotinib would put a stop to tumor cell proliferation.
EGFR family receptors mutations or overexpression have been linked to several cancer types. Besides the NSCLS, they were also detected in gastric and breast cancer.
Poziotinib is currently being tested in a number of mid-stage trials targeting breast cancer patients.
According to the Spectrum presentation, it is also proving its usefulness in treating non-small lung cancer cells.
Computational models of the early study show that its size may be one of the contributing factors. The smaller structure could potentially overcome steric hindrance.
Based on the favorable early preclinical study results, a clinical study could be soon to follow. Such a trial, which would be investigator-sponsored, would seek to determine poziotinib effects on NSCLC.
It would include 20 NSCLC patients with the EGFR exon 20 mutant and could start enrolling targeted participants quite soon.
Image Source: Wikimedia